EGFR and lung cancer: Altogether, these findings demonstrate the synergistic therapeutic effects of combining As2O3 and TKIs, such as afatinib and erlotinib, in lung cancer cells and suggest a potentially effective approach to overcoming the acquired resistance of EGFR-mutant and EGFR wild-type lung cancer cells to EGFR TKIs.